maraviroc

1 April 2013. Related: ARVs, CCR5 inhibitors, Entry inhibitors.

ma-RAV-veer-ok

• Maraviroc (tradenames Celsentri in Europe and Selzentry in the US) is a CCR5 inhibitor.
• Standard doses: 1 x 150, 300 or 600 mg tablet depending on the other drugs in the combination. Available as 150 mg and 300 mg tablets.
• Dosing is “as prescribed” as maraviroc can be once-daily or twice-daily depending on the other drugs in the combination.
• Maraviroc can be taken with or without food.
• Side effects: rash, muscle and joint pain, stomach pain, dizziness. Maraviroc may affect your heart – caution is recommended for people with a high risk of cardiovascular disease.
• Other notes: maraviroc is not generally used in first combinations.
• Before taking this drug you must have a special test to see if this drug will work against your type of HIV. This will be a special resistance test in Europe or a tropism test in the US. Maraviroc will only work if you have “R5” virus. If you have “X4” virus or a mixture of X4 and R5 virus maraviroc is not recommended.
• Contains soya lecithin and the SPC include a caution not use maraviroc if you have soya or nut hypersensitivity allergies.

Further information

The European patient information and detailed Product Information for maraviroc are available from this link on the European Medicines Agency (EMA) website.

The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.

The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.